[go: up one dir, main page]

BR9713400A - Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis. - Google Patents

Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.

Info

Publication number
BR9713400A
BR9713400A BR9713400-7A BR9713400A BR9713400A BR 9713400 A BR9713400 A BR 9713400A BR 9713400 A BR9713400 A BR 9713400A BR 9713400 A BR9713400 A BR 9713400A
Authority
BR
Brazil
Prior art keywords
synthesis
amyloid peptide
compounds
processes
release
Prior art date
Application number
BR9713400-7A
Other languages
Portuguese (pt)
Inventor
James E Audia
Thomas C Britton
James J Droste
Beverly K Folmer
George W Huffman
Varghese John
Lee H Latimer
Thomas E Mabry
Jeffrey S Nissen
Warren J Porter
Jon K Reel
Eugene D Thorsett
Jay S Tung
Jing Wu
Clark Norman Eid
William Leonard Scott
Original Assignee
Elan Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc
Publication of BR9713400A publication Critical patent/BR9713400A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção:<B>"PROCESSOS E COMPOSTOS PARA INIBIR LIBERAçãO DE PEPTìDEO BETA-AMILóIDE E/OU SUA SìNTESE"<D>. São revelados compostos que inibem a liberação de peptídeo <225>-amilóide e/ou síntese e, consequentemente, possui utilidade no tratamento da doença de Alzheimer. Também são reveladas composições farmacêuticas compreendendo um composto que inibe a liberação de peptídeo <225>-amilóide e/ou sua síntese, bem como processos para tratamento da doença de Alzherimer ambas, profilática e terapeuticamente com tais composições farmacêuticas.Invention Patent: <B> "PROCESSES AND COMPOUNDS TO INHIBIT BETA-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS" <D>. Compounds are disclosed that inhibit the release of <225> -amyloid peptide and / or synthesis and, consequently, have utility in the treatment of Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound that inhibits the release of β-amyloid peptide and / or its synthesis, as well as processes for treating Alzherimer disease both prophylactically and therapeutically with such pharmaceutical compositions.

BR9713400-7A 1996-11-22 1997-11-21 Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis. BR9713400A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US80852897A 1997-02-28 1997-02-28
US80752897A 1997-02-28 1997-02-28
US80742797A 1997-02-28 1997-02-28
PCT/US1997/020804 WO1998022494A2 (en) 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS

Publications (1)

Publication Number Publication Date
BR9713400A true BR9713400A (en) 2000-01-25

Family

ID=27505670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713400-7A BR9713400A (en) 1996-11-22 1997-11-21 Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.

Country Status (21)

Country Link
EP (1) EP0942924A2 (en)
JP (1) JP2001503782A (en)
KR (1) KR20000069064A (en)
CN (1) CN1238779A (en)
AR (1) AR016751A1 (en)
AU (1) AU5356198A (en)
BR (1) BR9713400A (en)
CA (1) CA2267634A1 (en)
CO (1) CO4910156A1 (en)
CZ (1) CZ122899A3 (en)
EA (1) EA199900490A1 (en)
HR (1) HRP970627A2 (en)
HU (1) HUP0100270A3 (en)
ID (1) ID22044A (en)
IL (1) IL129083A0 (en)
NO (1) NO992368L (en)
NZ (1) NZ334690A (en)
PE (1) PE16999A1 (en)
TR (3) TR199901133T2 (en)
WO (1) WO1998022494A2 (en)
YU (1) YU46097A (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1089980A1 (en) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1093372A4 (en) * 1998-06-22 2004-09-29 Elan Pharm Inc CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
EP1131634A2 (en) 1998-09-30 2001-09-12 Elan Pharmaceuticals, Inc. Determining the mechanism of beta-amyloid peptide generation
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CA2352740A1 (en) 1998-12-10 2000-06-15 F. Hoffmann-La Roche Ag Procollagen c-proteinase inhibitors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
MXPA01011341A (en) * 1999-05-07 2002-06-21 Texas Biotechnology Corp Propanoic acid derivatives that inhibit the binding of integrins to their receptors.
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
CA2388750A1 (en) * 1999-11-09 2001-05-17 James Edmund Audia .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
CA2400226C (en) 2000-03-31 2007-01-02 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
HK1049333A1 (en) 2000-06-01 2003-05-09 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
DE10143840A1 (en) * 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
PL370324A1 (en) 2001-11-09 2005-05-16 Aventis Pharma S.A. 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
EA007434B1 (en) 2002-02-28 2006-10-27 Прозидион Лимитед Glutaminyl based dpiv inhibitors
ES2387803T3 (en) * 2003-01-08 2012-10-02 Novartis Vaccines And Diagnostics, Inc. Antibacterial agents
KR20110059664A (en) 2003-05-05 2011-06-02 프로비오드룩 아게 Use of Effectors of Glutaminyl and Glutamate Cycase
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005027969A1 (en) * 2003-09-24 2005-03-31 Santen Pharmaceutical Co., Ltd. Remedy for eye diseases accompanied by optic nerve injuries
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
EP4274559A4 (en) * 2021-01-05 2024-12-11 Southern Research Institute MODULATORS OF LIGAND-1 FOR PROGRAMMED CELL DEATH
WO2024076635A2 (en) * 2022-10-05 2024-04-11 Buck Institute For Research On Aging Suppressors of site iq electron leak and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910713A1 (en) * 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
ZA945719B (en) * 1993-08-09 1996-02-01 Lilly Co Eli Identification and use of protease inhibitors
PT721449E (en) * 1993-10-01 2002-06-28 Merrell Pharma Inc BETA-AMYLOID PROTEIN PRODUCTION INHIBITORS
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
WO1996039194A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof

Also Published As

Publication number Publication date
EA199900490A1 (en) 2000-02-28
YU46097A (en) 2000-10-30
KR20000069064A (en) 2000-11-25
EP0942924A2 (en) 1999-09-22
HUP0100270A2 (en) 2001-08-28
AR016751A1 (en) 2001-08-01
NO992368L (en) 1999-06-21
HRP970627A2 (en) 1998-08-31
TR199901133T2 (en) 1999-07-21
NO992368D0 (en) 1999-05-14
WO1998022494A2 (en) 1998-05-28
HUP0100270A3 (en) 2001-09-28
AU5356198A (en) 1998-06-10
PE16999A1 (en) 1999-02-19
CO4910156A1 (en) 2000-04-24
IL129083A0 (en) 2000-02-17
CZ122899A3 (en) 1999-10-13
ID22044A (en) 1999-08-26
CN1238779A (en) 1999-12-15
NZ334690A (en) 2001-09-28
WO1998022494A3 (en) 1998-11-26
TR199902937T2 (en) 2001-01-22
CA2267634A1 (en) 1998-05-28
TR199902938T2 (en) 2002-06-21
JP2001503782A (en) 2001-03-21

Similar Documents

Publication Publication Date Title
BR9713400A (en) Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
BR9713404A (en) esters of n- (aryl / heteroarylacetyl) amino acids, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds.
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
BG101118A (en) Therapeutical compounds
BR0008922A (en) Compounds useful as anti-inflammatory agents
GB0129260D0 (en) Pharmaceutical compositions and their uses
NO961326L (en) Inhibitors of -amyloid protein production
DE69738581D1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
BR0115427A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating Alzheimer&#39;s disease, and for preventing the disease and the progress of Alzheimer&#39;s disease, and, use of a compound.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
BR9913072A (en) Azacyclic ring systems, pharmaceutical composition, and process to induce analgesia
EA199700032A1 (en) DISINFECTING COMPOSITION &#34;VELTOLEN&#34;
BR9712141A (en) Application of 1-hyphroxy-2-pyridones to treat skin infections.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer&#39;s disease
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
AU4568400A (en) Sphingomyelinase inhibitor
DE69420574D1 (en) DERIVATIVES OF THERAPEUTICALLY EFFECTIVE PEPTIDES IN THE BLOOD COLLECTING CASCADE, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
ECSP972320A (en) METHODS AND COMPOSITIONS FOR INHIBITING THE RELEASE OF β-AMYLOID PEPTIDE AND / OR ITS SYNTHESIS
UA31266A (en) MEDICAL MEDICINE &#34;DIALGIN&#34;

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007.